KING OF PRUSSIA, PA – Oct. 7, 2015– The image of staid psychiatrists trying their best to help their patients find a solution to their mental health concerns without the benefit of the latest technology is becoming as outdated as the slide rule. Mental Illness Awareness Week Oct. 4–10 and World Mental Health Day on Oct. 10 provide important opportunities to share the latest about advancements revolutionizing patient care.
The Genecept Assay from Genomind is a genetic test designed to help clinicians optimize treatment decisions for their patients with mental illness. It identifies patientspecific genetic markers that indicate which treatments are likely to work as intended,have no effect or cause adverse effects. This removes the guesswork for clinicians by helping them choose more effective medications and dosages.
“We have successfully used the Genecept Assay with more than 200 patients as they have sought solutions to depression, anxiety, bipolar disorder and other issues. This genetic testing provides patients with the answers they need for quicker and more efficient drug treatments. Oftentimes we see patients when they are frustrated after trying many other options that haven’t worked,” says Dr. Michelle Cochran, medical director, Nashville Center for Hope & Healing. Dr. Cochran also trains other physicians on the practical use
of genetic testing in a clinical environment.
Dr. Bibi Das specializes in treating obsessive-compulsive disorder and bipolar disorder at her practice in Palo Alto, Calif. “I found the genetic test results are a relief for patients…They are glad to know it is ‘not them’ but rather some genetic variant that is causing their symptoms. With that buy in, I focus on using the genetic information to give personalized medicine, which is a huge step in the right direction.”
The Genecept Assay is an easily administered cheek swab test that analyzes key genes that are selected based on hundreds of studies showing that variations in these genes can inform treatment decisions. The Assay is used to guide treatment for a range of psychiatric conditions, including depression, anxiety, ADHD, bipolar disorder, PTSD and schizophrenia.
Peer-reviewed published studies have shown the Assay improves patient outcomes and reduces overall medical costs. Each Assay provides clinicians with an easy-to-read patient report and a complimentary psychopharmacologist consultation. Clinicians and patients are benefiting from the Genecept Assay in all 50 states. An open label study found 87 percent of patients showed clinically measurable improvement after treatment using the Genecept Assay, far exceeding trial-and-error treatment.
Genomind is a personalized medicine company bringing innovation to mental health care through genetic testing. Genomind is comprised of pioneering researchers and thought leaders in psychiatry and neurology and specializes in pharmacogenetic laboratory testing for psychiatry. Genomind is committed to partnering with clinicians to improve their patients’ lives.